Settlement Structure: Claims Made
Closed Settlement Statement:
According to court documents, the claim submission deadline has passed. Please contact the claims administrator if you have any questions.Case Summary:
GlaxoSmithKline, Inc. and GlaxoSmithKline, LLC are settling a class action centering on their drug Avandia. The complaint alleged that people who took Avandia suffered heart attacks or congestive heart failure or needed coronary artery bypass grafts or percutaneous coronary intervention.Docket Number:
Company: GlaxoSmithKline Inc.
Filing Deadline: July 15, 2020
Class Period: December 1, 2010
Final Approval Hearing: June 13, 2019Proof of Purchase:
Claimants must show documentation of Avandia use and medical records of subsequent problems.Eligibility:
You may be a Primary Class Member if you are a person in Canada (or their estate) who used Avandia for at least thirty continuous days, beginning before December 2010 and who suffered one of the following injuries within one year of such use: myocardial infarction (heart attack), congestive heart failure, coronary artery bypass graft (CABG surgery), and percutaneous coronary intervention with stent placement.
You may be a Family Class Member if you are the spouse, child, grandchild, parent, grandparent or sibling of a deceased member of the Primary Class.Typical Settlement Amount:
Compensation varies according to a number of factors. The final settlement amount will also vary, depending on the claims received.
Total Settlement Amount: $4,116,666.67 (CDN) - $6,750,000.00Class Representative Proposed Incentive Fee:
Case Name: Albert Carl Sweetland and Barbara Fontaine v. GlaxoSmithKline Inc. and GlaxoSmithKline LLC
Settlement Website: Avandia Use and Cardiovascular Injuries Settlement Website
RicePoint Administration Inc.
Avandia Class Action
c/o RicePoint Administration Inc.
PO Box 4454, Toronto Station A
25 The Esplanade
Toronto, ON M5W 4B1